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Abstract 
Dilated cardiomyopathy (DCM) is the third most common cause of 
heart failure. The multidisciplinary nature of testing — involving 
genetics, imaging, or cardiovascular techniques — makes its 
diagnosis challenging. Novel and reliable biomarkers are needed 
for early identification and tailored personalized management. 
Peripheral circular RNAs (circRNAs), a leading research 
topic, remain mostly unexplored in DCM. We aimed to assess 
whether peripheral circRNAs are expressed differentially among 
etiology‑based DCM. The study was based on a case–control 
multicentric study. We enrolled 130 subjects: healthy controls 
(n = 20), idiopathic DCM (n = 30), ischemic DCM (n = 20), and 
familial DCM patients which included pathogen variants of 
(i) LMNA gene (n = 30) and (ii) BCL2‑associated athanogene 3 
(BAG3) gene (n = 30). Differentially expressed circRNAs were 
analyzed in plasma samples by quantitative RT‑PCR and cor‑
related to relevant systolic and diastolic parameters. The patho‑
physiological implications were explored through bioinformatics 
tools. Four circRNAs were overexpressed compared to controls: 
hsa_circ_0003258, hsa_circ_0051238, and hsa_circ_0051239 
in LMNA‑related DCM and hsa_circ_0089762 in the ischemic 
DCM cohort. The obtained areas under the curve confirm the 
discriminative capacity of circRNAs. The circRNAs correlated 
with some diastolic and systolic echocardiographic parameters 
with notable diagnostic potential in DCM. Circulating circRNAs 
may be helpful for the etiology‑based diagnosis of DCM as a 
non‑invasive biomarker.
Key messages 
• The limitations of cardiac diagnostic imaging and the 
absence of a robust biomarker reveal the need for a diag‑
nostic tool for dilated cardiomyopathy (DCM).
• The circular RNA (circRNA) expression pattern is para‑
mount for categorizing the DCM etiologies.
• Our peripheral circRNAs fingerprint discriminates 
between various among etiology‑based DCM and cor‑
relates with some echocardiographic parameters.
• We provide a potential non‑invasive biomarker for the 
etiology‑based diagnosis of LMNA‑related DCM and 
ischemic DCM.
Keywords Circulating circular RNA · Ischemic‑dilated 
cardiomyopathy · Lamin A/C‑dilated cardiomyopathy
Introduction
Heart failure is a global pandemic affecting more than 25 
million people worldwide, with a continuously increasing 
prevalence [1]. One of the major causes of heart failure is 
dilated cardiomyopathy (DCM), characterized by chamber 
enlargement and contractile dysfunction of the left ventricle 
(LV) [2]. Several etiologies are included in the DCM com‑
mon pathway. Ischemic cardiomyopathy is more common 
than non‑ischemic (59% compared with 41%) [2]. Among 
non‑ischemic cardiomyopathy, up to 35% of idiopathic DCM 
may have a family history [2, 3]. Pathogenic alterations in 
the gene encoding nuclear lamin A and C proteins‑lamin 
A/C (LMNA) explain 5–10% of familial DCM cases.
DCM is a heterogeneous entity that has different outcomes 
and may require diverse therapies [4]. Notably, ischemic and 
familial DCM are major groups with life‑threatening arrhyth‑
mias [3]. LMNA‑related DCM presents highly aggressive out‑
comes and lethal ventricular arrhythmias [5]. Male sex, LV 
ejection fraction (LVEF) lower than 50%, and non‑missense 
mutations are independent predictors of adverse outcome [6]. 
Thus, the identification of DCM etiology may help clinicians 
to stratify patients at risk of fatal events. However, the diag‑
nosis process to reach DCM etiology involves several clinical 
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steps. Multidisciplinary teams, imaging tests, the high cost of 
genetic testing, and its low efficiency make DCM etiologic 
diagnosis challenging. A precise, accessible biomarker that 
supports this process is required to improve diagnosis and 
early identification of asymptomatic cases. This would facili‑
tate the adoption of tailored management.
Non‑coding RNAs have pivotal roles in regulating the net‑
work that governs the physiology and pathology of cardio‑
vascular diseases [7]. To date, microRNAs (miRNAs) have 
been considered a more relevant biomarker candidate due 
to the complexity of circular RNA (circRNA) assessment in 
human screening [8]. However, circRNAs also have thought‑
provoking features. The advantages of circRNAs are their cell 
type, tissue, and developmental stage specificity. Furthermore, 
they are independently regulated and more stable than lineal 
RNA, and they are gathered in cells and human body fluids [8]. 
CircRNAs modulate gene expression by sponging miRNAs, 
interacting with RNA‑binding proteins (RBPs), and compet‑
ing with canonical splicing of their pre‑mRNA precursor [9]. 
Research reporting circRNAs as an effective diagnostic and 
therapeutic biomarker in many diseases has grown exponen‑
tially in the last decade. Nevertheless, the potential of using 
this easy‑to‑monitor and highly stable marker for stratifying 
DCM etiologies remains unexplored. Additionally, the experi‑
mental and computational analyses of these molecular cross‑
regulations will propel new insights on DCM [8].
Fig. 1  Flowchart of the study 
design strategy. This figure 
illustrates the experimental 
workflow of the study includ‑
ing screening, validation, and 
peripheral circRNAs over‑
expressed for the LMNAPh−, 
LMNAPh+, and ischemic DCM 
cohort. Abbreviations: BAG3, 
BCL2‑associated athanogene 3; 
DCM, dilated cardiomyopathy; 
lamin A/C; LMNAPh−, LMNA 
carrier of the pathogenic vari‑
ant; LMNAPh+, LMNA carrier 
phenotype positive; LVEF, left 
ventricle ejection fraction
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Table 1  Study population: anthropometric, clinical, and echocardiographic variables
All values are expressed as mean ± SEM
A atrial systolic transmitral flow wave, A’s TDI atrial septal mitral annular velocity, BAG3 BCL2‑associated athanogene 3, BMI body mass index, 
DBP diastolic blood pressure, DCM dilated cardiomyopathy, E early diastolic transmitral flow wave, E′ early diastolic mitral annular velocity, LA 
left atrial, LAD left atrial dimension, LMNA lamin A/C, LMNAPh− LMNA carrier of the pathogenic variant, LMNAPh+ LMNA carrier phenotypi‑
cally positive, LVEDD left ventricular end‑diastolic dimension, LVEF left ventricle ejection fraction, LVESD left ventricle end‑systolic dimen‑
sion, MAPSE mitral annular plane systolic excursion, NYHA New York Heart Association classification, RV right ventricle, S’ positive systolic 




Idiopathic (N = 30) LMNAPh− (N = 12) LMNAPh+ (N = 18) BAG3 (N = 30) Ischemic (N = 20)
Age (years) 42.0 ± 11.0 63.7 ± 8.2 40.6 ± 6.9 38.7 ± 15.0 42.2 ± 14.8 71.1 ± 8.5
Sex (male) 55% 70% 23.1% 42.9% 68.4% 72.2%
BMI (kg/m2) 25.1 ± 3.3 26.7 ± 2.6 25.4 ± 2.1 23.6 ± 3.9 27.9 ± 4.9 28.8 ± 4.9
Heart rate (bpm) 65.7 ± 11.9 71 ± 13.9 65.7 ± 5.9 64.3 ± 9.9 73 ± 10 64.6 ± 16.8
Smoker 0% 60% 57.1% 30.8% 26.3% 22.2%
SBP (mm Hg) 114.5 ± 8.7 113.1 ± 11.9 128.4 ± 15.9 123.2 ± 20.9 128.1 ± 13.3 124.3 ± 12.7
DBP (mm Hg) 73.5 ± 8.5 73.1 ± 7.1 81.8 ± 6.1 76.7 ± 17.9 81.1 ± 7.8 72.2 ± 8.6
LVEF (%) 68.8 ± 6.0 30.5 ± 10.2 44.5 ± 5.0 61.0 ± 5.9 49.5 ± 11.9 34.7 ± 7.5
LVEDD (mm) 47.7 ± 4.8 63.0 ± 3.8 58.0 ± 3.4 49.2 ± 12.6 55.6 ± 7.5 58.6 ± 4.8
LVESD (mm) 30.0 ± 6.9 48.1 ± 16.8 43.8 ± 3.1 30.7 ± 6.8 40.4 ± 9.3 44.1 ± 13.2
LA volume (mL/m2) 17.4 ± 4.3 71.1 ± 25.0 49.3 ± 12.4 41.0 ± 15.5 68.2 ± 25.8 62.1 ± 19.6
LAD (mm) 35.1 ± 5.4 45.2 ± 9.1 40.8 ± 4.3 33.8 ± 6.6 37.6 ± 6.5 40.8 ± 6.1
RV (mm) 28.6 ± 3.5 39.7 ± 6.5 31.7 ± 1.9 28.8 ± 5.2 32.1 ± 7.6 31.4 ± 6.9
TAPSE 22.2 ± 2.7 18.2 ± 6.4 21.6 ± 3.6 21.3 ± 3.5 21.1 ± 5.4 18.8 ± 3.9
MAPSE 18.1 ± 1.6 9.6 ± 2.7 12.1 ± 3.1 16.0 ± 2.6 12.3 ± 3.2 10.6 ± 2.1
E (cm/s) 0.7 ± 0.2 0.7 ± 0.2 0.8 ± 0.1 0.8 ± 0.2 0.8 ± 0.3 0.8 ± 0.2
A (cm/s) 0.6 ± 0.1 0.8 ± 0.3 0.7 ± 0.3 0.5 ± 0.2 0.6 ± 0.2 0.8 ± 0.3
S’sTDI (cm/s) 0.08 ± 0.01 0.06 ± 0.06 0.06 ± 0.01 0.08 ± 0.02 0.08 ± 0.01 0.05 ± 0.01
E’s TDI (cm/s) 0.09 ± 0.03 0.05 ± 0.05 0.07 ± 0.02 0.10 ± 0.04 0.09 ± 0.04 0.05 ± 0.01
A’s TDI (cm/s) 0.10 ± 0.03 0.06 ± 0.02 0.11 ± 0.02 0.09 ± 0.04 0.11 ± 0.03 0.07 ± 0.03
E/E’ ratio 7.7 ± 2.1 16.3 ± 8.5 10.2 ± 3.0 7.9 ± 2.2 6.3 ± 1.5 15.0 ± 6.4
NYHA functional class (II‑III) 0% 10% 14.3% 15.4% 10.5% 11.1%
The present study aimed to identify differentially 
expressed circRNAs in the plasma of patients with DCM of 
various etiologies such as familial, idiopathic, or ischemic.
Material and methods
Study design
The study was based on a case–control multicentric study. 
Patient samples and the dataset were collected from several 
centers (Puerta del Mar University Hospital, Cádiz; Cruz 
Roja Hospital, Madrid; and Virgen de la Victoria Univer‑
sity Hospital, Málaga, Spain). We enrolled 130 subjects 
distributed in five study groups: healthy controls (n = 20), 
idiopathic DCM (n = 30), ischemic DCM (n = 20), and 
familial DCM patients. The carriers of rare pathogenic 
variants included were (i) LMNA gene (n = 30) and (ii) 
BCL2-associated athanogene 3 (BAG3) gene (n = 30) 
(Fig. 1).
DCM etiology was determined by three independent 
clinical cardiologists, who are experts in cardiomyopa‑
thies. DCM was defined as either LVEF levels below 50% 
and/or LV end‑diastolic diameter larger than 56 mm [10]. 
BAG3 and LMNA participants were confirmed genetically 
and fulfilled the diagnostic clinical criteria for familial 
DCM [11]. The LMNA cohort was subclassified as a car‑
rier of the pathogenic variant, phenotypically negative 
(LMNAPh−) and genetically and phenotypically positive 
(LMNAPh+) as previously described [11]. Genetic etiology 
was ruled out in all idiopathic DCM patients. Ischemic 
DCM was diagnosed if a precedent of acute myocardial 
infarction or coronary artery disease was shown, which 
developed LV remodeling and dysfunction [10]. A tran‑
sthoracic echocardiography protocol was performed as 
described previously [11, 12]. The information included 
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anthropometric, clinical, therapeutic, electrocardio‑
graphic, and echocardiographic data from electronic medi‑
cal records (Table 1).
Ethics
The study protocol was approved by the Andalusian Bio‑
medical Research Ethics committee. The study was per‑
formed in full compliance with the Declaration of Helsinki. 
All participants provided written informed consent.
Genetic analysis
Genetic analysis was performed as previously described 
[11]. DNA isolation was undertaken using Chemagic 
MSM I from whole blood (Chemagic Human Blood). 
DNA integrity was assessed on 0.8% agarose gel and the 
quality ratios of absorbance were accomplished using 
spectrophotometric measurements. dsDNA concentration 
was determined using fluorometry integrity (Qubit, Life 
Technologies) and corroborated on 0.8% agarose gel.
Blood collection
Ten milliliters of peripheral blood was collected in 
K2‑ethylenediaminetetraacetic acid tubes (BD) after 10 h 
overnight fasting. None of the patients was under heparin 
therapy. The blood was processed within 4 h after isola‑
tion, centrifuged (1500 g, 15 min, 4 °C), and the plasma 
layer was aliquoted and stored at − 80ºC until further 
analysis.
Microarray analysis
A screening study was carried out using the Arraystar 
Human Circular RNA Microarray V2.0 (Arraystar, Inc.). 
This platform analyzed 36 samples of idiopathic and non‑
idiopathic DCM subjects. Total RNAs from each sample 
were obtained using the Arraystar’s standard protocols 
(Arraystar, Inc.). The enriched circRNAs were amplified and 
transcribed into fluorescent cDNA using a random priming 
method (Arraystar Super RNA Labeling Kit; Arraystar). The 
labelled cDNAs were hybridized onto the Arraystar Human 
circRNA Array V2.0 (Arraystar, Inc.). Once the slides had 
been washed, they were scanned by the Agilent Scanner 
G2505C.
RNA isolation and quantitative reverse 
transcriptase‑polymerase chain reaction
Total RNA was isolated from 200 µL of plasma using a 
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with 20 µL of RNase‑free  H2O and stored at − 80 °C. For 
the circRNA quantification, circulating RNA preparations 
were reverse transcribed with a first‑strand cDNA synthesis 
kit (Nzytech, Portugal) using a random primer approach 
and following the manufacturer’s instructions. Previous to 
reverse transcription, samples were spiked with MS2 RNA 
(Sigma‑Aldrich, Germany), which was used as an internal 
normalizer. Quantification of selected circRNAs was per‑
formed by qRT‑PCR using divergent DNA primers designed 
with the circInteractome algorithm [13] (see Supplemental 
Table 1 for primer sequences) in an Applied Biosystems by 
the qRT‑PCR system. Fold‑change analysis between sample 
groups was calculated by the Delta‑Ct method.
Fig. 2  Boxplots of circRNA expression levels, normalized to MS2 
RNA, in healthy subjects, BAG3‑related DCM, idiopathic DCM, 
ischemic DCM, and LMNA‑related DCM. The analysis was car‑
ried out using qRT‑PCR. Data are present in  log2. Data represent 
the mean ± SEM. *p < 0.05. Abbreviations: BAG3, BCL2‑associated 
athanogene 3; CT, healthy cohort; circRNA, circular RNA; DCM, 
dilated cardiomyopathy; LMNA, lamin A/C; LMNAPh−, LMNA carrier 
of the pathogenic variant; LMNAPh+, LMNA carrier phenotype posi‑
tive
Table 3  Comparisons of single 
circRNA as predictors of DCM
AUC area under the curve, CI confidence interval, DCM dilated cardiomyopathy, LMNA lamin A/C
DCM etiology circRNA AUC (95% CI) Sensitivity (%) Specificity (%) p
LMNA hsa_circ_0003258 0.75 (0.56–0.94) 61.53 78.57 0.043
hsa_circ_0051238 0.71 (0.53–0.88) 70 72.73 0.02
hsa_circ_0051239 0.73 (0.61–0.93) 83.33 72.23 0.007
Ischemic hsa_circ_0089762 0.92 (0.77–1) 83.33 72.73 0.006
Functional enrichment
Information about circRNAs is available on the circBase 
website (http:// www. circb ase. org/). The Circular RNA 
Interactome (https:// circi ntera ctome. nia. nih. gov/) was 
used to predict miRNAs and RBP‑binding sites. The reg‑
ulatory network was performed with Navigator software 
[14]. The set of RBPs common to all the differentially 
expressed circRNAs was analyzed with STRING: func‑
tional protein association networks (https:// string‑ db. 
org) [15]. The set of miRNAs common to all the differen‑
tially expressed circRNAs was analyzed with miRNet 2.0 
(https:// www. mirnet. ca/ miRNet/ home. xhtml).
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Statistical analysis
Continuous variables are expressed as the mean ± standard 
deviation. Categorical variables are expressed in frequency and 
percentage (%). Analysis of variance was applied to compare 
intergroup circRNAs levels. The Pearson correlation was used 
to test the link between echocardiographic and clinical vari‑
ables vs.  log2 circRNAs. In addition, the association between 
circRNAs and echocardiography parameters was assessed 
using logistic bivariate regression. Several models were con‑
structed using the Wilcoxon test and iterating combinations 
between our circRNA candidates, as well as echocardiographic 
and clinical covariates. The changes in p‑values of their vari‑
ables were evaluated by the Wald test and a likelihood ratio. 
To characterize the diagnostic performance of the circRNAs 
candidate, ROC curves were applied together with a logistic 
regression model to determine the AUC and the specificity 
and sensitivity of the optimal cutoffs. ROC curves were gener‑
ated by plotting sensitivity against 100‑specificity. Data were 
presented as the AUC and 95% CI. The statistical software 
package R (www.r‑ proje ct. org) was used for all analyses.
Results
Analysis of circRNA expression profiles in plasma 
of DCM patients
A total of 36 idiopathic and non‑idiopathic DCM age‑
matched patients were assessed to test the differences in 






































































































































































































































































































































































































































































































Table 5  Correlation between the clinical parameters and hsa_
circ_0089762 for ischemic DCM cohort
DCM dilated cardiomyopathy, DBP diastolic blood pressure, LVEF 
left ventricle ejection fraction
hsa_circ_0089762
Pearson r p Power
DBP (mm Hg) ‑0.84 0.036 0.556
LVEF (%) ‑0.842 0.036 0.561
Fig. 3  Bivariate logistic regression analysis for LMNA‑related DCM 
and ischemic DCM patients. A–F Logistic regression analysis for 
the LMNA‑related DCM cohort. LVEF was independently nega‑
tively related with hsa_circ_0003258 (A), hsa_circ_0051238 (B), and 
hsa_circ_0051239 (C). D RV tricuspid annular plane systolic excur‑
sion (TAPSE) was negatively related to hsa_circ_0003258. E, F LV 
mitral annular plane systolic excursion (MAPSE) was negatively cor‑
related with hsa_circ_0003258 and hsa_circ_0051238. G, H The levels 
of hsa_circ_0089762 were associated with A’s TDI (G) and RV (H). 
The odds ratio, 95% of CI, and p values are indicated for each logistic 
regression analysis. Abbreviations: A’s TDI, atrial septal mitral annular 
velocity; AUC, area under the curve; CT, healthy group; CI, confidence 
intervals; LMNA, lamin A/C gene; LVEF, left ventricle ejection frac‑
tion; MAPSE, mitral annular plane systolic excursion; OR, odd ratio; 
RV; right ventricle; TAPSE, tricuspid annular plane systolic excursion
◂
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and 2). A total of ten candidate circRNAs (see Supple‑
mentary Table 2) were obtained from circRNA micro‑
array screening of plasmatic samples (fold change > 2, 
p < 0.05).
Validating the expression of the candidate circRNAs
The expression of the ten circRNA candidates was car‑
ried out in plasma samples of each study group, using 
qRT‑PCR. Only LMNA and ischemic DCM populations 
showed differential circRNA expression (Table 2). Cir‑
culating levels of hsa_circ_0051238, hsa_circ_0051239, 
and hsa_circ_0003258 were highly upregulated in the 
LMNA population compared to healthy controls (Fig. 2). 
To assess the strength of circRNAs as an early bio‑
marker before the clinical manifestation of malignant 
ventricular arrhythmias and LV dilation, the LMNA‑
related DCM group was subdivided into LMNA patho‑
genic variant carrier, phenotypically negative (LMNAPh−) 
and phenotypically positive (LMNAPh+). Circulating 
hsa_circ_0003258 levels were differentially expressed 
in the LMNAPh− (LMNAPh− p = 0.03, LMNAPh+ p = 0.03) 
(Fig. 2A). The hsa_circ_0051238 levels were differen‑
tially expressed in the LMNAPh− population (p = 0.03) 
(Fig.  2B). And, the hsa_circ_0051239 plasmatic lev‑
els were significantly higher in both LMNA groups 
(LMNAPh− p = 0.03, LMNAPh+ p = 0.04) than in healthy 
subjects (Fig. 2C). Regarding the ischemic DCM cohort, 
the plasma hsa_circ_0089762 levels were significantly 
higher (p = 0.04) than in healthy subjects (Fig. 2D).
Diagnostic value of the validated circRNAs in a DCM 
population
The receiver operating characteristic (ROC) area under 
the curve (AUC) analysis was assessed to investigate 
the circulating circRNAs diagnostic value in discrimi‑
nating LMNA and ischemic DCM etiology from healthy 
controls. All individual circRNAs show an AUC ≥ 0.7. 
The highest AUC values reached by hsa_circ_0089762 
that demonstrated an AUC value of 0.92 (95% of confi‑
dence intervals [CI] range of specificities are shown in 
Table 3).
Fig. 4  CircRNA‑centered regulatory network established among 
the selected circRNAs. The depicted interactions are based on data 
extracted from the circInteractome database and include miRNAs 
and RBPs. CircRNAs are represented as squares, RBPs as circles and 
miRNAs as triangles. The size of each symbol is proportional to the 
number of interactions established. The edge thickness is also propor‑
tional to the number of targets for each interacting partner as included 
in the circInteractome database. The regulatory network was prepared 
with Navigator software [14]. Abbreviations: DCM, dilated cardio‑
myopathy; LMNA, lamin A/C gene; miRNA, microRNA; RBP, RNA‑
binding protein
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Association between the expression of circRNAs 
and the clinical characteristics of the DCM 
population
The association between circulating circRNAs and echo‑
cardiographic and clinical features of DCM patients was 
also analyzed. As indicated in Table 4, the LMNAPh− group 
showed a negative correlation between hsa_circ_0003258 
and hsa_circ_0051239 with early diastolic mitral annular 
velocity (E’s TDI). The LMNAPh+ cohort showed a positive 
correlation of hsa_circ_0051238 with tissue Doppler imag‑
ing (TDI) septal atrial systolic mitral annular velocity (A’s 
TDI) and a negative correlation of hsa_circ_0051238 and 
hsa_circ_0051239 with LV outflow tract (LVOT) velocity.
An additional study was performed to assess cor‑
relations between the echocardiographic and clinical 
Table 6  Differentially expressed circRNA potentially interact with RBP and miRNAs
DCM dilated cardiomyopathy, LMNA lamin A/C, RBP RNA‑binding protein
DCM etiology circRNA RBP Predicted miRNAs target
LMNA hsa_circ_003258 AGO2, EIF4A3, HuR, IGF2BP1, IGF2BP2 hsa‑miR‑502‑5p
hsa_circ_0051238 AGO2, EIF4A3, FMRP, HuR, IGF2BP1, IGF2BP2, 
IGF2BP3, LIN28A, RBPMS, ZC3H7B
hsa‑miR‑1208, hsa‑miR‑1281, hsa‑miR‑1305, 
hsa‑miR‑1827, hsa‑miR‑198, hsa‑miR‑210, 
hsa‑miR‑326, hsa‑miR‑330‑5p, hsa‑miR‑370, hsa‑
miR‑377, hsa‑miR‑503, hsa‑miR‑513a‑3p, hsa‑
miR‑513a‑5p, hsa‑miR‑515‑5p, hsa‑miR‑517b, 
hsa‑miR‑518a‑5p, hsa‑miR‑543, hsa‑miR‑589, 
hsa‑miR‑600, hsa‑miR‑640, hsa‑miR‑658, 
hsa‑miR‑663b, hsa‑miR‑665, hsa‑miR‑758, 
hsa‑miR‑766, hsa‑miR‑767‑3p, hsa‑miR‑873, 
hsa‑miR‑874, hsa‑miR‑885‑3p, hsa‑miR‑891a, 
hsa‑miR‑891b, hsa‑miR‑892a, hsa‑miR‑892b, 
hsa‑miR‑940
hsa_circ_0051239 AGO2, EIF4A3, FMRP, HuR, IGF2BP1, IGF2BP2, 
IGF2BP3, LIN28A, RBPMS
hsa‑miR‑1184, hsa‑miR‑1208, hsa‑miR‑1281, 
hsa‑miR‑1305, hsa‑miR‑188‑3p, hsa‑miR‑198, 
hsa‑miR‑210, hsa‑miR‑326, hsa‑miR‑370, hsa‑
miR‑377, hsa‑miR‑496, hsa‑miR‑503, hsa‑miR‑
513a‑3p, hsa‑miR‑513a‑3p, hsa‑miR‑513a‑5p, 
hsa‑miR‑518a‑5p, hsa‑miR‑543, hsa‑miR‑589, 
hsa‑miR‑605, hsa‑miR‑637, hsa‑miR‑640, hsa‑
miR‑658, hsa‑miR‑663b, hsa‑miR‑665, hsa‑
miR‑767‑3p, hsa‑miR‑885‑3p, hsa‑miR‑885‑5p, 
hsa‑miR‑891b, hsa‑miR‑892a, hsa‑miR‑892b, 
hsa‑miR‑940
Ischemic hsa_circ_0089762 AGO1, AGO2, DGCR8, EIF4A3, FMRP, IGF2BP1, 
IGF2BP2, IGF2BP3, LIN28A, LIN28B, METTL3, 
TNRC6
hsa‑miR‑183, hsa‑miR‑21, hsa‑miR‑361‑3p, hsa‑
miR‑433, hsa‑miR‑590‑5p
Table 7  Pathway analysis main findings: PPI enrichment analysis
PPI enrichment p‑value:1.67e − 10
FDR false discovery rate, GO gene ontology, KW keyword
Pathway Overlap FDR Genes Database
Regulation of translation 7/327 2.09e − 10 AGO2,EIF4A3,ELAVL1,FMRP,IGF2BP1,IGF2BP2,IGF2BP3 GO
mRNA binding 7/198 1.31e − 12 AGO2,EIF4A3,ELAVL1,FMRP,IGF2BP1,IGF2BP2,IGF2BP3 GO
Negative regulation of nitrogen com‑
pound metabolic process
7/2307 8.81e − 06 AGO2,EIF4A3,ELAVL1,FMRP,IGF2BP1,IGF2BP2,IGF2BP3 GO
Regulation of mRNA stability 5/113 1.05e − 08 ELAVL1,FMRP,IGF2BP1,IGF2BP2,IGF2BP3 GO
mRNA transport 5/148 3.12e − 08 EIF4A3,FMRP,IGF2BP1,IGF2BP2,IGF2BP3 GO
Regulation of gene silencing by miRNA 3/78 3.82e − 05 AGO2,ELAVL1,FMRP GO
Regulation of membrane potential 2/408 0.0445 EIF4A3,FMRP GO
MAPK6/MAPK4 signaling 2/86 0.0077 AGO2,IGF2BP1 GO
ncRNA processing 2/340 0.0344 AGO2,EIF4A3 GO
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variables and hsa_circ_0089762 for the ischemic DCM 
population. Hsa_circ_0089762 expression was negatively 
associated with diastolic blood pressure and LVEF (see 
Table 5).
To further explore the expression of circRNA‑DCM 
disease association, a logistic regression analysis was 
carried out in our DCM population (Fig. 3). All three 
LMNA‑linked circRNAs were significantly related to male 
gender hsa_circ_0003258, hsa_circ_0051238, and hsa_
circ_0051239. In the LMNA cohort, the bivariate logistic 
regression analyses revealed that all LVEF were indepen‑
dently negatively associated with hsa_circ_0003258, hsa_
circ_0051238, and hsa_circ_0051239. LV mitral annular 
plane systolic excursion was independent negatively asso‑
ciated with hsa_circ_0003258 and hsa_circ_0051238. 
Right ventricle (RV) tricuspid annular plane systolic 
excursion was only independently negatively associated 
with hsa_circ_0003258. Pulmonary hypertension (PHT) 
was independently positively related to hsa_circ_0003258 
and hsa_circ_0051239.
In the case of hsa_circ_0089762, the logistic regression 
analysis showed that its circulating levels within A’s TDI 
wave or the RV dimension were independent influencing 
factors for ischemic DCM.
Annotation for circRNA/RBPs interaction
An examination of biological processes related to RBPs, 
with binding sites for circRNA candidates, reveals a set 
of possible pathways in which circRNAs play a regulative 
role. LMNA mutation influences the proper development 
of megakaryocytes resulting in altered platelet produc‑
tion/function [16]. We recovered this LMNA effect in the 
enrichment (GO:0,045,652), regulation of megakaryocyte 
differentiation (FDR = 0.0013), and fibroblast growth 
(GO:0,008,543) (FDR = 0.0267).
The analysis of the intersection set of RBPs predicted 
to interact with the selected circRNAs (Fig. 4; Table 6) 
shows clear enrichment in proteins involved in the control 
of transcriptional and translational processes (Table 7). 
Note the association with the regulation of membrane 
potential, in which IEF4A3 and FMRP are involved 
(FDR = 0.045).
The analysis of miRNAs sponged by validated cir‑
cRNAs offers various candidates for further research. 
Hsa_circ_0003258 has only one functional binding site 
to hsa‑miR‑653. As a counterpart, hsa_circ_0051238 
and hsa_circ_0051239 present a clear sponge effect over 
hsa‑miR‑210, with five binding sites that have ∆U below 
zero. Thereby, the overexpression of hsa_circ_0051238 
and hsa_circ_0051239 will actively reduce the availabil‑
ity of hsa‑miR‑210. Hsa‑miR‑210 regulates expression of 
hepatocyte growth factor gene, whose overexpression is 
considered a treatment for DCM [17]. Additionally, they 
also present a functional binding site for hsa‑miR‑330‑5p 
that is involved in cardiomyocyte survival and func‑
tion recovery [18]. Regarding miRNA‑related diseases, 
hsa_circ_0051238 sponges hsa‑miR‑873 and hsa‑miR‑
513a‑5p are both related with heart disease (p = 0.075), 
and hsa‑miR‑377 is related with ischemic cardiomyopathy 
(p = 0.221). Hsa_circ_0089762 has sponge activity with 
multiple, energetically favorable binding sites. Of note 
is hsa‑miR‑21, as well as hsa‑miR‑183, hsa‑miR‑361‑3p, 
hsa‑miR‑384, hsa‑miR‑873, hsa‑miR‑938, hsa‑miR‑1249, 
and hsa‑miR‑1283. The miRNAs sponged by the circRNAs 
with a context score over 90% was used to capture the set 
of mRNAs regulated by these miRNAs. Functional enrich‑
ment, using a hypergeometric association algorithm, shows 
that 148 proteins of the network were related with focal 
adhesion (p = 2.68e−8), and 128 proteins were linked with 
regulation of the actin cytoskeleton (p = 0.00002). Gene 
ontology biological processes, using the same hypergeo‑
metric algorithm, show a significant correlation with endo‑
plasmic reticulum‑nuclei signaling pathways (p = 0.1e−6) 
and pre‑ and post‑Golgi vesicle transportation (p = 8.6e−7 
and 4.47e−7, respectively).
Discussion
Over the last decade, the diagnostic process of DCM eti‑
ologies has focused on searching for new biomarkers. An 
efficient biomarker for DCM should be robust, stable, 
non‑invasive, sensitive, specific to this entity, predic‑
tive of a particular DCM etiology, and show a preclinical 
and clinical relevance to be validated in animal and/or 
human cell models [19]. We propose the use of periph‑
eral circRNAs as a novel discriminant biomarker of DCM 
etiologies.
Unlike linear RNA, single circulating circRNAs or 
circRNAs combined with various other biomarkers are 
a promising tool for clinical diagnosis of heart diseases, 
which would improve outcome [20]. Thus, circRNA 
MICRA was reported to risk‑stratify patients after acute 
myocardial infarction [21]. Peripheral circ_0124644 and 
circ_0098964 levels have been described as a diagnostic 
biomarker of coronary artery disease [22]. Related to car‑
diomyopathies, a set of circulating circRNAs DNAJC6, 
TMEM56, and MBOAT2 has been proposed to discrimi‑
nate between healthy and hypertrophic cardiomyopathy 
[23]. In this sense, hsa_circ_0071542 was upregulated in 
children with fulminant myocarditis in leukocytes isolated 
from peripheral blood [24]. Nevertheless, this area remains 
mostly unexplored in DCM [22, 25]. Recent studies have 
described several circRNA expression profiles in the DCM 
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population compared to healthy patients. However, to date, 
it has not been studied among the different etiologies of 
DCM [26, 27]. Hence, further analysis of circRNAs among 
DCM etiologies might provide early, precise characteriza‑
tion of the disease and lead to novel pathological informa‑
tion, beyond the traditional biomarkers. To the best of our 
knowledge, the present study is the first to describe a subset 
of circulating circRNA for a discriminative etiology‑based 
diagnostic in DCM. Circulating hsa_circ_0003258, hsa_
circ_0051238, and hsa_circ_0051239 expression levels 
were upregulated in LMNA‑related DCM patients. Nota‑
bly, hsa_circ_0051238 plasmatic levels were significantly 
present in the LMNAPh− cohort. Hence, it may be a prom‑
ising diagnostic biomarker for the early identification of 
patients in an initial stage of LMNA‑related DCM. This will 
allow personalized therapeutic measures to be applied that 
help to improve the progression and outcome of LMNA‑
related DCM. Furthermore, plasmatic hsa_circ_0089762 
may provide discriminative power for the ischemic DCM 
cohort with high‑yield diagnostic accuracy and an AUC 
of 0.92. These circRNAs have been identified mostly in 
various types of oncologic processes [28–33]. Thus, only 
hsa_circ_0051239 levels have been upregulated in the 
myocardium of congenital ventricular septal defect [33]. 
However, they have not been previously described in DCM 
cases.
In the current study, circRNA were related to clinical 
and echocardiographic variables. Male gender, rare non‑
missense variants in LMNA and LVEF < 50% have been 
established as independent factors associated with a more 
aggressive outcome and even death during follow‑up [34]. 
Herein, all three circRNAs associated with LMNA-DCM eti‑
ology were related to male gender [35]. On the other side, 
echocardiography variables and related circRNAs might 
suggest a time‑evolving sequence. TDI echocardiography is 
a non‑invasive, very sensitive method to assess the cardiac 
hemodynamic in DCM [36]. TDI reveals that subtle impair‑
ments in diastolic myocardial tissue velocities are markers of 
early cardiac disease and have been associated with outcome 
in various cardiopathies [16, 17]. In the LMNAPh− group, 
the E’s TDI is negatively related to hsa_circ_0003258 and 
hsa_circ_0051239. This E’s TDI impairment suggests an 
underlying early diastolic dysfunction [37]. A’s TDI in the 
LMNAPh+ group showed a positive correlation, which indi‑
cates that the left atrium is a prominent factor to maintain 
the LV filling pressure when diastolic dysfunction advances. 
This sequential TDI septal impairment mirrors the transition 
from LMNAPh− to LMNAPh+ and may be related to the pro‑
gressive fibrosis of the interventricular septum located in the 
basal portion, which is characteristic of the LMNA related‑
DCM that has been associated with ventricular arrhythmias 
and worse prognosis [38]. LVEF was independently nega‑
tively associated with hsa_circ_0003258, hsa_circ_0051238, 
and hsa_circ_0051239. According to the LV systolic impair‑
ment, hsa_circ_0003258 and hsa_circ_0051238 were related 
to LV mitral annular plane systolic excursion. Thus, changes 
in contractility quantified by LV mitral annular plane sys‑
tolic excursion occur as compensatory mechanisms before 
impairment of ventricular function [39]. Hsa_circ_0051238 
and hsa_circ_0051239 were also negatively related to LVOT 
velocity, which suggests progressive impairment of the car‑
diac pump in the LMNAPh+ cohort. Dysfunction of RV is a 
final common step in DCM and heart failure [40]. RV pres‑
sure overload due to PHT and the interventricular interde‑
pendence affected by septal fibrosis and underlying ischemia 
may influence this situation. In support of our results, cir‑
cRNA, hsa_circ_0003258 was positively increased with the 
RV lower tricuspid annular plane systolic excursion and 
PHT [41].
Otherwise, hsa_circ_0089762 correlated to diastolic 
blood pressure and LVEF in the ischemic group, which 
supports our results as a specific, highly sensitive bio‑
marker with high‑yield diagnostic accuracy. Moreover, 
hsa_circ_0089762 was related to A’s TDI, which suggests 
more advanced progression of this entity. Its association 
with an increase in RV dimension could add information 
for tailored management in this group, since RV impair‑
ment is a worse outcome marker in the ischemic popula‑
tion [42]. In addition, RV involvement has a multifactorial 
origin that may be influenced by LV remodelling, increased 
LV filling pressures, and the appearance of PHT or RV 
ischemia [43].
Regarding biological implications, circRNAs spring 
from introns or exons of their parental genes by back‑
spliced circularization [25]. Hence, the ratio between linear 
and circular fractions affects gene expression. According 
to the protein atlas (proteinatlas.org), parental genes are 
expressed in cardiac tissue, which supports correlations 
between etiologies and circRNAs. Hsa_circ_0003258 is 
synthesized from ZNF652 gene. ZNF652 interacts with 
CBFA2T3, which acts as a transcriptional repressor [44]. 
ZNF652 is associated with systolic or diastolic blood pres‑
sure and hypertension. However, its role remains unclear 
[45]. Hsa_circ_0051238 and hsa_circ_0051239 come from 
the ATP5SL gene. ATP5SL is required for the assembly of 
mitochondrial NADH: ubiquinone oxidoreductase com‑
plex (complex I). Complex I is essential to provide the 
energy for cardiac function and is related to DCM pro‑
gression [46]. ATP5SL has been associated with a con‑
genital ventricular septal defect by the overexpression of 
hsa_circ_0051239 [47]. Finally, hsa_circ_0089762 is gen‑
erated from the MT-CO2 gene. MT‑CO2 is part of the elec‑
tron transport chain of the mitochondria. Reduced activity 
of the electron transport chain subunits has been described 
independently of etiology in ischemic or idiopathic DCM 
patients [48].
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The functional enrichment of the intersecting set of 
RBSs reveals the role of FMRP in regulation of the mem‑
brane potential. Bao et al. described FMRP isoform 1, in 
rats, as an essential protection factor and a novel potential 
biomarker in the cardiovascular system [49]. The par‑
ticipation of circRNAs in regulatory networks involving 
competing‑endogenous RNA interactions by sequestering 
miRNAs has been characterized recently in cardiovascular 
pathologies [50, 51]. From the set of miRNAs that could 
be sponged by the circRNAs that we considered, we found 
significant enrichment in the regulation of focal adhesion 
and actin cytoskeleton. Both have an important role in 
human DCM [52], which suggests new pathways of study.
Our current study has several limitations. Firstly, our 
sample was prospectively recruited from the outpatient 
clinic. The size of the study sample, comprised of strictly 
DCM patients, did not allow us to obtain a robust multivari‑
ate logistic regression model. Furthermore, a larger sample 
size is needed to validate these data by gender categoriza‑
tion since gender may play a role in the DCM prognosis 
[53, 54]. In consequence, these results should be extended 
and replicated to a larger population before the novel bio‑
markers can be routinely applied in clinical practice. Fur‑
thermore, data on natriuretic peptides or troponin were not 
accessible for all patients. Finally, even though databases 
registered the expression of the parental genes in cardiac 
tissue, we have no confirmation about the direct secretion 
from the heart of these circulating circRNAs into the extra‑
cellular space. Hence, the association of circRNAs with 
DCM and all the interactions are putative. Further analysis 
should be carried out on human heart samples to confirm 
our results.
Conclusion
Exploring new biomarkers through circular transcriptome 
expression patterns will identify new targets in DCM patho‑
genesis. We propose a circulating circRNAs fingerprint to 
discriminate between various DCM etiologies. Circulating 
hsa_circ_0003258, hsa_circ_0051238, and hsa_circ_0051239 
expression levels are higher in LMNA‑related DCM, and 
hsa_circ_0089762 levels are specifically upregulated in the 
ischemic DCM cohort. These circulating circRNAs and cer‑
tain echocardiographic variables might improve the etiology‑
based diagnostic, which allows early identification of asymp‑
tomatic cases and tailored treatment of the DCM population.
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